Single-stranded positive-sense RNA viruses account for a large number of clinically serious global pathogens and are the cause of many potentially life-threatening diseases: coronaviruses, including SARS-CoV-2, the virus responsible for COVID-19, dengue, yellow fever, Ebola, Zika, West Nile, encephalitis viruses, hepatitis C, and RSV.
The activity of a key viral enzyme, RNA-dependent RNA polymerase, also known as RNA polymerase, is required for replication and propagation of these viruses. The structure of this enzyme is highly conserved across RNA viruses. Most viral RNA polymerases have been identified on the basis of comparative sequence analysis, but it is important to know that viral genome replication is initiated by two different and distinct mechanisms.
We have produced a large library of nucleoside and nucleotide analogs prodrugs that specifically target viral RNA polymerases. Based on extensive knowledge and years of experience discovering and developing antivirals, our team of scientists has designed product candidates that include specific chemical modifications intended to enhance antiviral activity and maximize selectivity.
Unique prodrugs of nucleotide analogs are intrinsic to Atea’s innovative platform for developing orally administered, direct-acting antiviral therapies.
A platform of proprietary purine nucleos(t)ide prodrugs designed specifically to target viral RNA polymerase.
Nucleos(t)ide drugs are well suited for mono- and combination treatment regimens.
Treatment of most RNA viral diseases require combination regimens to prevent drug resistance
SARS-CoV-2 and Future Coronaviruses
HCV
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with serious viral infections. Currently, Atea is focused on the development of orally-available antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV).
Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatments.
Copyright © 2020 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use